All In Biotech

Drug Trial Radar · NCT04401384

Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy

Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy: A Randomized Controlled Two-by-two Factorial Trial

Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

352

Actual

Start

Jun 21, 2020

Primary completion

Jun 23, 2021

Study completion Jan 31, 2022

Sponsor

Lead sponsor
Xiaoke WuAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ningxia Hui Autonomous Region Hospital of TCM; Jiangxi Maternal and Child Health Hospital; Jixi Maternal and Child Health Hospital; Luoyang Hospital of TCM; Xuzhou Central Hospital; First Affiliated Hospital of Heilongjiang Chinese Medicine University; Shuangyashan Maternal and Child Health Hospital; Heilongjiang Provicial Hospital; Jiamusi Maternal and Child Health Hospital; Hegang Maternal and Child Health Hospital; Suihua Maternal and Child Health Hospital; Mudanjaing Maternal and Child Health Hospital; Affiliated Hospital of Jiamusi Medical University
First posted
May 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nausea and vomiting in pregnancy (NVP) is one of the most common symptoms of pregnancy affecting 50-85% of women during the first half of pregnancy. Maternal morbidity is common and includes psychological effects, financial burden, clinical complications from nutritional deficiencies, gastrointestinal trauma, and in rare cases, neurological damage. As the main means of alternative treatment, economical and easy to obtain; the clinical efficacy of acupuncture treatment of this disease has low level of evidence and needs to be reconfirmed. Doxylamine vitamin B6 sustained release tablets (Diclectin, combination of doxylamine succinate (10mg) and pyridoxine hydrochloride (10mg) are The American College of Obstetricians and Gynecologists recommends with Level A evidence the use of vitamin B6 in combination with doxylamine as first-line pharmacotherapy for treatment of NVP. The efficacy and safety of Diclectin has been confirmed in many years of research, but there is no evidence of high-level evidence-based medicine for the Chinese population. The purpose of this multicenter, randomized, double-blind, placebo-controlled trial was to investigate the efficacy and safety of acupuncture versus Diclectin in the treatment of NVP. We hypothesis that: (1)Sham acupuncture and Diclectin (Arm B) is more effective than sham acupuncture and placebo (Arm D); (2)Active acupuncture and placebo (Arm C) is more effective than sham acupuncture and placebo (Arm D); (3) There is no interaction (either synergistic or antagonistic effects) between the two interventions of active acupuncture and Diclectin in patients with NVP.

Conditions

  • Nausea and Vomiting of Pregnancy

Interventions

  • DiclectinDrug

    Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.

  • Diclectin placeboDrug

    Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.

  • Active acupunctureDevice

    Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).

  • Sham acupunctureDevice

    Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Score change of pregnancy unique quantification of emesis (PUQE) scale from baseline to day 15Time frame: Baseline to day 15; Scores ranged 3 to 15, with higher scores indicating more

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Heilongjiang Chinese Medicine University

    Harbin, Heilongjiang, China

  • Heilongjiang provincial hospital

    Harbin, Heilongjiang, China

  • Hegang Maternal and Child Health Hospital

    Hegang, Heilongjiang, China

  • Affiliated Hospital of Jiamusi Medical University

    Jiamusi, Heilongjiang, China

  • Jiamusi Maternal and Child Health Hospital

    Jiamusi, Heilongjiang, China

  • Jixi Maternal and Child Health Hospital

    Jixi, Heilongjiang, China

  • Mudanjaing Maternal and Child Health Hospital

    Mudanjiang, Heilongjiang, China

  • Shuangyashan Maternal and Child Health Hospital

    Shuangyashan, Heilongjiang, China

  • Suihua Maternal and Child Health Hospital

    Suihua, Heilongjing, China

  • Luoyang Hospital of TCM

    Luoyang, Henan, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, China

  • Ningxia Hui Autonomous Region Hospital of TCM

    Yinchuan, Ningxia, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.